Wave Life Sciences Ltd.
NASDAQ:WVEBiotechnology
+$0.10 today
- Market cap
- $546.32M
- Beta
- -1.33
- P/E (TTM)
- -6.6
- EPS (TTM)
- -$0.92
Volume 2.21M
Average 4.86M
WVE Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Wave Life Sciences Ltd.NASDAQ: WVE
Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026
Accounts receivables dips below year-ago levels
Q1 FY2026 accounts receivables of $1.28M fell 10.3% year over year, behind the +291.8% change in trailing-twelve-month accounts receivables. Sequentially, it fell 85.7% from the prior quarter.
Context
- Accounts receivables amounted to 0.3% of revenue in FY2025, down 17.8 pp from a year earlier.
- Accounts receivables increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -10.3% toward the trailing-twelve-month pace of +291.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- 146K USD
- Year-over-year change
- -99.3%
- 4-year CAGR
- -73.6%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 146K | -99.3% |
| FY2024 | 2024-12-31 | 19.66M | +193.3% |
| FY2023 | 2023-12-31 | (21.09M) | — |
| FY2022 | 2022-12-31 | 0 | -100.0% |
| FY2021 | 2021-12-31 | 30M | — |
Accounts Receivables vs competitors
How WVE compares with its peers on the latest reported figures
- Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +291.8% is the 2nd highest of 9, against a peer median of -3.8%.
- Accounts receivables amounts to 0.2% of revenue for WVE, versus a peer median of 7.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $357.64M USD | +48.4% | +99.1% | 7.4% | |
| LTM Mar 2026 | $264.55M USD | +194.3% | — | 12.1% | |
| LTM Sep 2026 | $63.73M USD | -14.2% | -10.4% | 6.6% | |
| LTM Mar 2026 | $13.31M USD | +6.6% | — | 29.4% | |
| LTM Mar 2026 | $8.33M USD | — | — | 904.4% | |
| LTM Mar 2026 | $4.8M USD | +1478.7% | — | 15.0% | |
| LTM Sep 2026 | $3.29M USD | -94.2% | — | 0.7% | |
| LTM Mar 2026 | $1.37M USD | -94.7% | -18.2% | 2.1% | |
| LTM Mar 2026 | $177.78K USD | +291.8% | — | 0.2% | |
| LTM Mar 2026 | $8.07K USD | -96.4% | +481.9% | — | |
| LTM Mar 2026 | €0 EUR | — | — | 0.0% | |
| Peer median (excluding WVE) | — | -3.8% | +44.3% | 7.4% | |
Competitors are the stored peer set for WVE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (122.25M) | (161.82M) | (57.51M) | (97.01M) | (204.38M) |
| Depreciation & Amortization | 9.84M | 10.11M | 9.21M | 8.66M | 8.85M |
| Deferred Income Tax | (12.64M) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 16.41M | 17.19M | 9.8M | 13.14M | 0 |
| Change in Working Capital | 7.01M | 6.72M | 19.08M | (75.82M) | (16.94M) |
| Accounts Receivables | 30M | 0 | (21.09M) | 19.66M | 146K |
| Inventory | 2.04M | 0 | 0 | 0 | 0 |
| Accounts Payables | (6.57M) | 9.35M | (3.76M) | 3.42M | (561K) |
| Other Working Capital | (18.46M) | (2.63M) | 43.93M | (98.91M) | (16.53M) |
| Other Non-Cash Items | 12.64M | 12K | 0 | 0 | 24.97M |
| Operating Cash Flow | (88.99M) | (127.78M) | (19.43M) | (151.03M) | (187.49M) |
| Capital Expenditures | (560K) | (1.36M) | (1.12M) | (938K) | (718K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (75.04M) | 0 | 0 | 0 |
| Sales of Investments | 0 | 75.04M | 0 | 0 | 0 |
| Other Investing Activities | 0 | 106K | 0 | 0 | 0 |
| Investing Cash Flow | (560K) | (1.26M) | (1.12M) | (938K) | (718K) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 54.97M | 52.33M | 131.28M | 236.18M | 488.24M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 858K | 14.86M | 1.26M | 17.71M | 0 |
| Financing Cash Flow | 55.83M | 67.19M | 132.53M | 253.89M | 488.24M |
| Effect of Forex Changes | (208K) | (210K) | (95K) | (138K) | 12K |
| Net Change in Cash | (33.93M) | (62.06M) | 111.89M | 101.79M | 300.04M |
| Free Cash Flow | (89.55M) | (129.14M) | (20.55M) | (151.96M) | (187.49M) |
Wave Life Sciences Ltd.
NASDAQ:WVE
Intrinsic Alpha fair value
Locked
Current Price
$2.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.